These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 33408257)

  • 1. MyD88 Costimulation in Donor CD8
    Ciavattone NG; Wu L; O'Neill R; Qiu J; Davila E; Cao X
    J Immunol; 2021 Feb; 206(4):892-903. PubMed ID: 33408257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Graft-versus-host disease after allogeneic hematopoietic stem cell transplantation induces a CD8+ T cell-mediated graft-versus-tumor effect that is independent of the recognition of alloantigenic tumor targets.
    Stelljes M; Strothotte R; Pauels HG; Poremba C; Milse M; Specht C; Albring J; Bisping G; Scheffold C; Kammertoens T; Oelmann E; Silling G; Berdel WE; Kienast J
    Blood; 2004 Aug; 104(4):1210-6. PubMed ID: 15090450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential Effect of MyD88 Signal in Donor T Cells on Graft-versus-Leukemia Effect and Graft-versus-Host Disease after Experimental Allogeneic Stem Cell Transplantation.
    Lim JY; Ryu DB; Lee SE; Park G; Choi EY; Min CK
    Mol Cells; 2015 Nov; 38(11):966-74. PubMed ID: 26552489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CTLA4-CD28 chimera gene modification of T cells enhances the therapeutic efficacy of donor lymphocyte infusion for hematological malignancy.
    Park HB; Lee JE; Oh YM; Lee SJ; Eom HS; Choi K
    Exp Mol Med; 2017 Jul; 49(7):e360. PubMed ID: 28751785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. During acute graft versus host disease CD28 deletion in donor CD8
    Uri A; Lühder F; Kerkau T; Beyersdorf N
    Eur J Immunol; 2018 Dec; 48(12):2055-2067. PubMed ID: 30320878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitochondrial Deacetylase SIRT3 Plays an Important Role in Donor T Cell Responses after Experimental Allogeneic Hematopoietic Transplantation.
    Toubai T; Tamaki H; Peltier DC; Rossi C; Oravecz-Wilson K; Liu C; Zajac C; Wu J; Sun Y; Fujiwara H; Henig I; Kim S; Lombard DB; Reddy P
    J Immunol; 2018 Dec; 201(11):3443-3455. PubMed ID: 30389773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A TLR5 agonist enhances CD8(+) T cell-mediated graft-versus-tumor effect without exacerbating graft-versus-host disease.
    Ding X; Bian G; Leigh ND; Qiu J; McCarthy PL; Liu H; Aygun-Sunar S; Burdelya LG; Gudkov AV; Cao X
    J Immunol; 2012 Nov; 189(10):4719-27. PubMed ID: 23045613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Host-derived CD8+ dendritic cells are required for induction of optimal graft-versus-tumor responses after experimental allogeneic bone marrow transplantation.
    Toubai T; Sun Y; Luker G; Liu J; Luker KE; Tawara I; Evers R; Liu C; Mathewson N; Malter C; Nieves E; Choi S; Murphy KM; Reddy P
    Blood; 2013 May; 121(20):4231-41. PubMed ID: 23520337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ceacam1 separates graft-versus-host-disease from graft-versus-tumor activity after experimental allogeneic bone marrow transplantation.
    Lu SX; Kappel LW; Charbonneau-Allard AM; Atallah R; Holland AM; Turbide C; Hubbard VM; Rotolo JA; Smith M; Suh D; King C; Rao UK; Yim N; Bautista JL; Jenq RR; Penack O; Na IK; Liu C; Murphy G; Alpdogan O; Blumberg RS; Macian F; Holmes KV; Beauchemin N; van den Brink MR
    PLoS One; 2011; 6(7):e21611. PubMed ID: 21760897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulating the conformation of the TIR domain by a neoteric MyD88 inhibitor leads to the separation of GVHD from GVT.
    Xing S; Zhang X; Huang X; Xie L; Jiang F; Zhou P
    Leuk Lymphoma; 2019 Jun; 60(6):1528-1539. PubMed ID: 30501537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New strategies in allogeneic stem cell transplantation: immunotherapy using irradiated allogeneic T cells.
    Waller EK; Boyer M
    Bone Marrow Transplant; 2000 May; 25 Suppl 2():S20-4. PubMed ID: 10933181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytotoxic Pathways in Allogeneic Hematopoietic Cell Transplantation.
    Du W; Cao X
    Front Immunol; 2018; 9():2979. PubMed ID: 30631325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Granzyme B-mediated damage of CD8+ T cells impairs graft-versus-tumor effect.
    Bian G; Ding X; Leigh ND; Tang Y; Capitano ML; Qiu J; McCarthy PL; Liu H; Cao X
    J Immunol; 2013 Feb; 190(3):1341-50. PubMed ID: 23264653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro and in vivo characterization of graft-versus-tumor responses in melanoma patients after allogeneic peripheral blood stem cell transplantation.
    Kurokawa T; Fischer K; Bertz H; Hoegerle S; Finke J; Mackensen A
    Int J Cancer; 2002 Sep; 101(1):52-60. PubMed ID: 12209588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Graft-vs.-lymphoma effect in an allogeneic hematopoietic stem cell transplantation model.
    Ito M; Shizuru JA
    Biol Blood Marrow Transplant; 1999; 5(6):357-68. PubMed ID: 10595813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineering hematopoietic grafts: purified allogeneic hematopoietic stem cells plus expanded CD8+ NK-T cells in the treatment of lymphoma.
    Verneris MR; Ito M; Baker J; Arshi A; Negrin RS; Shizuru JA
    Biol Blood Marrow Transplant; 2001; 7(10):532-42. PubMed ID: 11760085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Separation of graft-vs.-tumor effects from graft-vs.-host disease in allogeneic hematopoietic cell transplantation.
    Rezvani AR; Storb RF
    J Autoimmun; 2008 May; 30(3):172-9. PubMed ID: 18242060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The complex and central role of interferon-γ in graft-versus-host disease and graft-versus-tumor activity.
    Wang H; Yang YG
    Immunol Rev; 2014 Mar; 258(1):30-44. PubMed ID: 24517424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TLR agonists prevent the establishment of allogeneic hematopoietic chimerism in mice treated with costimulation blockade.
    Miller DM; Thornley TB; Pearson T; Kruger AJ; Yamazaki M; Shultz LD; Welsh RM; Brehm MA; Rossini AA; Greiner DL
    J Immunol; 2009 May; 182(9):5547-59. PubMed ID: 19380803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.